WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19

WHO today approved the decision by the International Steering Committee of the Solidarity Trial to discontinue the hydroxychloroquine and ritonavir arms of the court. In order to find successful COVID-19 care in hospitalized patients, WHO has developed the Solidarity Trial.

The International Steering Committee recommended the findings of the Solidarity interim study and reviewed evidences from all trials presented at the WHO COVID-19 Research and Development conference of 1-2 July with the evidence of hydroxychloroquine vs standard of care and for lopinavir / ritonavir vs. standard of care.

The interim study findings indicate that the mortality rate of hospitalized patients with COVID-19 in comparison to the standard of care is little to no decreased. The investigators of the Solidarity Check shall immediately interrupt the proceedings.

The intermediate findings for each drug do not show a significant increase in mortality. Nevertheless, the clinical laboratory results of the add-on Discovery research, which took part in the Solidarity report, showed some related safety signals. These are also mentioned in the publication reviewed by the peer.

This decision applies only to the Solidarity test in hospitalized patients, and does not impact the potential assessment of other COVID-19 pre- or post-exposure prophylaxis studies of non-hospitalized patients. The interim findings of Solidarity are now ready for publishing by peers.

Leave a Comment